Article
Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR.
Hepatology (Baltimore, Md.) - 1 Feb 2011
Thompson Alexander J, Santoro Rosanna, Piazzolla Valeria, Clark Paul J, Naggie Susanna, Tillmann Hans L, Patel Keyur, Muir Andrew J, Shianna Kevin V, Mottola Leonardo, Petruzzellis Daniela, Romano Mario, Sogari Fernando, Facciorusso Domenico, Goldstein David B, McHutchison John G, Mangia Alessandra
Abstract excerpt
UNLABELLED: Two functional variants in the inosine triphosphatase (ITPA) gene causing inosine triphosphatase (ITPase) deficiency protect against ribavirin (RBV)-induced hemolytic anemia and the need for RBV dose reduction in patients with genotype 1 hepatitis C virus (HCV). No data are available for genotype 2/3 HCV. We evaluated the association between the casual ITPA variants and on-treatment anemia in a...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
